Tiziana's experimental MS treatment meets main goals in mid-stage study

What happened

Tiziana Life Sciences said its experimental nasal treatment for non-active secondary progressive multiple sclerosis met both primary goals in a 48-patient mid-stage trial. The 50-microgram dose reduced brain inflammation versus placebo, both tested doses met safety goals, and patients reported reduced fatigue after 12 weeks.

Confirmed

Global impact / market context

The reported results could support further development of foralumab, but the study was small and the treatment remains experimental. If later evidence confirms benefit and safety, it could create a new treatment option and potential revenue for Tiziana in a form of multiple sclerosis the company says has no approved treatments.

Analyst inference

The trial results are early clinical evidence, not proof of approval or future sales. If further studies confirm benefit and safety, a treatment could eventually create revenue for Tiziana; setbacks could instead require more research spending and delay any commercial opportunity.

Analyst inference

What to watch

1. Watch for Tiziana’s next reported trial steps and whether studies involving more patients confirm reduced brain inflammation, fatigue benefits, and the safety findings seen here. Analyst inference
2. The article reports that the 50-microgram dose reduced brain inflammation versus placebo, while both doses met safety goals; no further study plans are stated. Confirmed
3. Track whether follow-up reports clarify how durable the fatigue reduction is and whether the listed side effects—headache, falls, congestion, and runny nose—remain manageable. Analyst inference

Evidence

• Original source link unavailable